logo
FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025: SNAP BENEFITS LINKED TO SLOWER COGNITIVE DECLINE, 10-YEAR STUDY FINDS

FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025: SNAP BENEFITS LINKED TO SLOWER COGNITIVE DECLINE, 10-YEAR STUDY FINDS

Cision Canada6 days ago
Key Takeaways
Participating in the Supplemental Nutrition Assistance Program (SNAP) may help protect against age-related cognitive decline, suggests an analysis of a national study.
Compared to non-participants, SNAP participants had a slower decline in cognitive function during the 10-year study period, effectively maintaining an average of two to three additional years of cognitive health.
Food insecurity can negatively impact cognitive function, and participating in SNAP may improve participants' diets and nutrition intake.
TORONTO, July 30, 2025 /CNW/ -- People who participated in the U.S. Supplemental Nutrition Assistance Program (SNAP) had slower cognitive decline over 10 years than those who didn't participate, according to new research being reported today at the Alzheimer's Association International Conference ® 2025 (AAIC ®), in Toronto and online.
The findings highlight the potential of food assistance programs to support cognitive health in the aging population and point to the need for additional efforts to reduce disparities in cognitive aging across different racial and ethnic groups, the researchers said. They also underscore the need for public health policies that ensure equitable access to programs like SNAP, which helps low-income individuals and families buy food, particularly for populations that may face additional barriers to enrollment.
Using the nationally representative Health and Retirement Study (HRS), researchers compared participants in SNAP to those who were eligible for the program but didn't participate. They determined that SNAP participants had a 0.10% slower decline in overall cognitive function, or two to three additional years of cognitive health over the 10-year period.
"Research has shown that food insecurity can negatively impact cognitive function, and this is one of the first long-term studies to show that food assistance programs can positively impact cognition," said Maria C. Carrillo, Ph.D., Alzheimer's Association chief science officer and medical affairs lead. "Simple, everyday actions can make a difference in brain health and may even lower the risk of Alzheimer's disease and dementia. The Alzheimer's Association is committed to helping all people build these habits into their daily lives, including eating right, one of our 10 Healthy Habits for Your Brain."
Researchers analyzed a racially and ethnically representative group of people age 50 and older comparing 1,131 (average age ~63 years) who were enrolled in SNAP in 2010 to 1,216 who were eligible for SNAP but did not participate (average age ~66 years). Memory and executive function — the ability to plan and carry out tasks — were assessed every two years between 2010 and 2020 via telephone or web-based interviews. People with an initial cognition summary score indicating cognitive impairment or dementia (11 or less out of 27 points) were excluded from the analysis.
While a 0.10-point difference in annual cognitive decline may seem small, the researchers note that its long-term impact is significant. "For someone starting at a healthy cognitive score, this slower decline could delay reaching the threshold for mild cognitive impairment by nearly a decade," said Linlin Da, MPH, lead author of the study and a Ph.D. candidate in health services research at the University of Georgia, Athens.
"This suggests SNAP participation, or another similar nutrition support program, could significantly delay the onset of cognitive impairment or dementia, allowing people to preserve their ability to manage medications, finances and daily tasks longer," said Da. "This ultimately supports greater independence and higher quality of life in older adulthood."
"At the same time, we discovered that this protective effect is not the same for everyone: non-Hispanic Black and Hispanic older adults did not benefit as much in cognitive functions compared to non-Hispanic white participants," Da added.
Comparing the cognitive findings for White, Black and Hispanic SNAP participants in the study to their peers who didn't participate in SNAP, the researchers found all three groups benefitted, but observed much stronger benefits and slower decline for the White SNAP participants.
"We hope health care providers will see that potentially delaying cognitive impairment is another reason to help their patients-in-need secure access to food assistance," said Suhang Song, Ph.D., corresponding author of the study and assistant professor in the department of health policy and management at the University of Georgia College of Public Health.
About the Alzheimer's Association International Conference ® (AAIC ®)
The Alzheimer's Association International Conference (AAIC) is the world's largest gathering of researchers from around the world focused on Alzheimer's and other dementias. As a part of the Alzheimer's Association's research program, AAIC serves as a catalyst for generating new knowledge about dementia and fostering a vital, collegial research community.
AAIC 2025 home page: www.alz.org/aaic/
AAIC 2025 newsroom: www.alz.org/aaic/pressroom.asp
AAIC 2025 hashtag: #AAIC25
About the Alzheimer's Association ®
The Alzheimer's Association is a worldwide voluntary health organization dedicated to Alzheimer's care, support and research. Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia ®. Visit alz.org or call 800.272.3900.
Linlin Da, MPH, et al. The association between Supplemental Nutrition Assistance Program participation and cognitive decline by racial/ethnic groups: a 10-year longitudinal study. (Funding: National Center for Advancing Translational Sciences of the National Institutes of Health UL1TR002378)
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Claigan Webinar - Are Canadian Products Safer than Products in Poland?
Claigan Webinar - Are Canadian Products Safer than Products in Poland?

Cision Canada

time13 minutes ago

  • Cision Canada

Claigan Webinar - Are Canadian Products Safer than Products in Poland?

For toxins in consumer products OTTAWA, ON, Aug. 5, 2025 /CNW/ - On 13 August 2025, Claigan Environmental Inc. ( will present and compare the findings of restricted materials testing on consumer products from Canada and Poland. Over the last two years, Claigan tested sixty (60) similar consumer products sourced from Canada and Poland for restricted materials. In particular, we focused on DEHP (which causes attention deficit) and lead (a reproductive toxin and carcinogen). This webinar will look at real restricted materials test data concerning products you buy and touch everyday. Whose products do you think have the higher risk? Is it Poland? Or is it Canada? Attend this webinar to find out. The main topics to be covered in this webinar are: Which products are safer? Levels of carcinogens and reproductive toxins Effects of the levels detected % of products tested with harmful levels of chemicals Comparison of product types and level of harm Are the same products found in the US and the rest of the EU? Due to the interest in these topics, two (2) webinars will be held on August 13 to accommodate a larger audience. About Claigan Environmental ( Claigan is the leading provider of restricted materials compliance. Claigan has tested tens of thousands of products for restricted materials compliance and offers complete cost effective solutions for even the most complex products. Claigan is an ISO 17025 certified laboratory and is dedicated to providing practical solutions for supply chain due diligence and social responsibility. At Claigan, we believe in 'Less Journey. More Results.'

BC Patient Calls for Equal Access to Life-Changing Treatment as Province Lags Behind Rest of Canada
BC Patient Calls for Equal Access to Life-Changing Treatment as Province Lags Behind Rest of Canada

Cision Canada

time8 hours ago

  • Cision Canada

BC Patient Calls for Equal Access to Life-Changing Treatment as Province Lags Behind Rest of Canada

VANCOUVER, BC, August 5, 2025 /CNW/ - Josephine (Joey) Kerr, a retired British Columbian who once led an active and vibrant life, is now calling on the provincial government to fund a life-changing medication that is available to patients in every other province in Canada—but not in BC. Joey was diagnosed with Myelodysplastic Syndromes (MDS) in 2019. Since then, she has undergone more than 85 blood transfusions - procedures that take an entire day and leave her exhausted for nearly half the month. "My life has changed drastically," says Joey. "I used to hike, bike, and swim regularly. Now I'm breathless, fatigued, and often too weak to leave the house." For patients like Joey, Luspatercept offers new hope. The medication significantly reduces the need for blood transfusions in MDS patients and is publicly covered in every other Canadian province. Despite its proven benefits, BC remains the only jurisdiction that has not approved public coverage. "It breaks my heart," says Joey. "I know of a woman in another province that went an entire year without a transfusion because of this medication." Beyond the personal toll, repeated transfusions place a significant strain on the healthcare system, requiring hospital resources, blood products, and specialized staff. "This isn't just about one person—it's about improving system efficiency and equity," says Joey. "I'm not asking for special treatment. I'm asking to be treated the same as other Canadians." MedAccessBC Urges Government to Take Action Joey's story highlights a larger, systemic issue that the Medicines Access Coalition – BC (MedAccessBC) has been working to address for over two decades. MedAccessBC represents over 30 patient care organizations and advocates for fair, timely, and equitable access to medications for British Columbians. "We are deeply concerned that patients in BC continue to face barriers to accessing treatments that are standard care in the rest of Canada," says Don Bindon, Co-Chair and Treasurer of MedAccessBC. "BC residents deserve the same level of care and access as all other Canadians. Luspatercept is a clear example where a delay in public coverage is causing unnecessary suffering." As a non-profit coalition, MedAccessBC continues to collaborate with patient communities, healthcare professionals, and policymakers to ensure that health decisions prioritize outcomes and do not compromise patient well-being in the name of cost containment. Call to Action MedAccessBC is urging the provincial government to approve and fund Luspatercept through the BC PharmaCare program without further delay. Joey Kerr's message to decision-makers is simple: "Help me live the rest of my life with dignity, energy, and independence. Let me have the chance to walk, swim, and maybe even ride my bike again." About Myelodysplastic Syndromes (MDS) Myelodysplastic syndromes (MDSs) are a group of diseases where bone marrow does not make enough healthy blood cells. Instead, the bone marrow makes immature blood cells, called blast cells (blasts), that do not work properly. They build up in the bone marrow and the blood and crowd out healthy blood cells. As a result, there are fewer healthy red blood cells, white blood cells, and platelets. In the past, an MDS was classified as a disease that was not likely to develop into cancer, and it was called pre-leukemia. Now that more is known about MDSs, they are considered cancer. Sometimes, they are called bone marrow failure diseases. An MDS will develop into acute myeloid leukemia (AML) about 30% of the time. (Canadian Cancer Society) About the Medicines Access Coalition of BC MedAccess BC advocates for improved access to medications and health technologies for individuals with chronic diseases. Representing over 30 patient organizations, it has been working since 1997 to improve access to evidence-based medicines through BC's PharmaCare program.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store